nodes	percent_of_prediction	percent_of_DWPC	metapath
Tasosartan—AGTR2—lung—esophageal cancer	0.0243	0.334	CbGeAlD
Tasosartan—Olmesartan—ABCC2—esophageal cancer	0.0215	0.378	CrCbGaD
Tasosartan—CYP3A4—Codeine and Morphine Metabolism—ABCC2—esophageal cancer	0.0148	0.017	CbGpPWpGaD
Tasosartan—AGTR2—Peptide ligand-binding receptors—SST—esophageal cancer	0.0144	0.0166	CbGpPWpGaD
Tasosartan—AGTR1—ACE Inhibitor Pathway—NOS3—esophageal cancer	0.0142	0.0164	CbGpPWpGaD
Tasosartan—AGTR2—Peptide ligand-binding receptors—GHRL—esophageal cancer	0.0141	0.0162	CbGpPWpGaD
Tasosartan—AGTR2—G alpha (i) signalling events—CXCL2—esophageal cancer	0.0135	0.0155	CbGpPWpGaD
Tasosartan—Candesartan—PTGS1—esophageal cancer	0.0126	0.222	CrCbGaD
Tasosartan—Irbesartan—PTGS1—esophageal cancer	0.0126	0.222	CrCbGaD
Tasosartan—AGTR1—neck—esophageal cancer	0.0126	0.173	CbGeAlD
Tasosartan—AGTR2—G alpha (i) signalling events—ANXA1—esophageal cancer	0.0125	0.0144	CbGpPWpGaD
Tasosartan—AGTR2—G alpha (i) signalling events—SST—esophageal cancer	0.0122	0.014	CbGpPWpGaD
Tasosartan—CYP3A4—Fatty Acid Omega Oxidation—ADH7—esophageal cancer	0.0117	0.0135	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.0107	0.0123	CbGpPWpGaD
Tasosartan—CYP3A4—Tryptophan metabolism—ALDH3A2—esophageal cancer	0.0103	0.0118	CbGpPWpGaD
Tasosartan—CYP3A4—Fatty Acid Omega Oxidation—ADH1B—esophageal cancer	0.0103	0.0118	CbGpPWpGaD
Tasosartan—AGTR1—Arf6 signaling events—MET—esophageal cancer	0.0102	0.0117	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.00995	0.0114	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.00968	0.0111	CbGpPWpGaD
Tasosartan—CYP3A4—Irinotecan Pathway—ABCC2—esophageal cancer	0.00947	0.0109	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.00943	0.0108	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.00932	0.0107	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—GNG7—esophageal cancer	0.00925	0.0106	CbGpPWpGaD
Tasosartan—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—esophageal cancer	0.0091	0.0105	CbGpPWpGaD
Tasosartan—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—esophageal cancer	0.00869	0.00998	CbGpPWpGaD
Tasosartan—AGTR1—epithelium—esophageal cancer	0.00855	0.118	CbGeAlD
Tasosartan—AGTR2—Signaling by GPCR—ADCYAP1—esophageal cancer	0.00847	0.00973	CbGpPWpGaD
Tasosartan—AGTR1—smooth muscle tissue—esophageal cancer	0.00824	0.113	CbGeAlD
Tasosartan—AGTR2—GPCR ligand binding—CXCL2—esophageal cancer	0.00815	0.00936	CbGpPWpGaD
Tasosartan—CYP3A4—Drug Induction of Bile Acid Pathway—ABCC2—esophageal cancer	0.00811	0.00932	CbGpPWpGaD
Tasosartan—CYP3A4—Codeine and Morphine Metabolism—ABCB1—esophageal cancer	0.00786	0.00903	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—GDI2—esophageal cancer	0.00776	0.00892	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—ANXA1—esophageal cancer	0.00758	0.0087	CbGpPWpGaD
Tasosartan—AGTR1—trachea—esophageal cancer	0.00756	0.104	CbGeAlD
Tasosartan—AGTR2—GPCR ligand binding—SST—esophageal cancer	0.00737	0.00847	CbGpPWpGaD
Tasosartan—CYP3A4—Fatty Acid Omega Oxidation—ALDH2—esophageal cancer	0.00724	0.00831	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—GHRL—esophageal cancer	0.00718	0.00825	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—ABCB1—esophageal cancer	0.00696	0.008	CbGpPWpGaD
Tasosartan—CYP3A4—Fatty Acid Omega Oxidation—CYP2A6—esophageal cancer	0.0068	0.00782	CbGpPWpGaD
Tasosartan—Candesartan—ABCB1—esophageal cancer	0.00614	0.108	CrCbGaD
Tasosartan—AGTR2—GPCR downstream signaling—AKAP13—esophageal cancer	0.00601	0.0069	CbGpPWpGaD
Tasosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—NOS3—esophageal cancer	0.00601	0.0069	CbGpPWpGaD
Tasosartan—AGTR1—G alpha (q) signalling events—GNG7—esophageal cancer	0.00598	0.00687	CbGpPWpGaD
Tasosartan—CYP3A4—Xenobiotics—CYP2A6—esophageal cancer	0.00569	0.00654	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—KMT2D—esophageal cancer	0.00561	0.00645	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—PDE4D—esophageal cancer	0.0055	0.00631	CbGpPWpGaD
Tasosartan—CYP3A4—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.00547	0.00629	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—AKAP13—esophageal cancer	0.00546	0.00627	CbGpPWpGaD
Tasosartan—AGTR1—lung—esophageal cancer	0.00543	0.0747	CbGeAlD
Tasosartan—AGTR1—GPCR ligand binding—ADCYAP1—esophageal cancer	0.00538	0.00618	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GNG7—esophageal cancer	0.00534	0.00614	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—GNG7—esophageal cancer	0.00523	0.006	CbGpPWpGaD
Tasosartan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.00523	0.006	CbGpPWpGaD
Tasosartan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.00523	0.006	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—CXCL2—esophageal cancer	0.0052	0.00597	CbGpPWpGaD
Tasosartan—AGTR1—Arf6 signaling events—EGFR—esophageal cancer	0.00518	0.00595	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—ADCYAP1—esophageal cancer	0.005	0.00575	CbGpPWpGaD
Tasosartan—CYP3A4—Estrogen metabolism—CYP1B1—esophageal cancer	0.00499	0.00573	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—PDE4D—esophageal cancer	0.00499	0.00573	CbGpPWpGaD
Tasosartan—AGTR1—G alpha (q) signalling events—ANXA1—esophageal cancer	0.00489	0.00562	CbGpPWpGaD
Tasosartan—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.00489	0.00562	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—ANXA1—esophageal cancer	0.00483	0.00555	CbGpPWpGaD
Tasosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—CDKN1A—esophageal cancer	0.0048	0.00552	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—GNG7—esophageal cancer	0.00475	0.00545	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—SST—esophageal cancer	0.0047	0.0054	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—CASP8—esophageal cancer	0.00467	0.00537	CbGpPWpGaD
Tasosartan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.00466	0.00535	CbGpPWpGaD
Tasosartan—AGTR1—G alpha (q) signalling events—GHRL—esophageal cancer	0.00464	0.00533	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—CXCL2—esophageal cancer	0.00461	0.00529	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—GHRL—esophageal cancer	0.00458	0.00526	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—WWOX—esophageal cancer	0.00457	0.00526	CbGpPWpGaD
Tasosartan—CYP3A4—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00441	0.00507	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—esophageal cancer	0.00438	0.00503	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—FKBP1A—esophageal cancer	0.00435	0.005	CbGpPWpGaD
Tasosartan—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—esophageal cancer	0.0043	0.00494	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—ANXA1—esophageal cancer	0.00428	0.00492	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—WIF1—esophageal cancer	0.00425	0.00489	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—CXCL2—esophageal cancer	0.00418	0.0048	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—SST—esophageal cancer	0.00416	0.00478	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—esophageal cancer	0.00415	0.00477	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—GHRL—esophageal cancer	0.00406	0.00466	CbGpPWpGaD
Tasosartan—Losartan—ABCB1—esophageal cancer	0.00396	0.0696	CrCbGaD
Tasosartan—AGTR2—Signaling Pathways—CSNK1A1—esophageal cancer	0.00392	0.00451	CbGpPWpGaD
Tasosartan—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.00391	0.00449	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—ANXA1—esophageal cancer	0.00389	0.00447	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—SST—esophageal cancer	0.00378	0.00434	CbGpPWpGaD
Tasosartan—AGTR1—lymph node—esophageal cancer	0.00371	0.0511	CbGeAlD
Tasosartan—AGTR2—Signaling by GPCR—GHRL—esophageal cancer	0.00369	0.00423	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PFN1—esophageal cancer	0.00367	0.00422	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.00349	0.00401	CbGpPWpGaD
Tasosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—PIK3CA—esophageal cancer	0.00338	0.00388	CbGpPWpGaD
Tasosartan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.00332	0.00381	CbGpPWpGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.0033	0.00379	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—ELMO1—esophageal cancer	0.0033	0.00379	CbGpPWpGaD
Tasosartan—CYP3A4—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.00327	0.00376	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.00324	0.00372	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—AKAP13—esophageal cancer	0.00322	0.0037	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.00315	0.00362	CbGpPWpGaD
Tasosartan—CYP3A4—Tryptophan metabolism—ALDH2—esophageal cancer	0.00311	0.00357	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.00307	0.00353	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.00304	0.00349	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—GNG7—esophageal cancer	0.00301	0.00346	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—HIST1H2BM—esophageal cancer	0.00297	0.00342	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PDE4D—esophageal cancer	0.00295	0.00339	CbGpPWpGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.00289	0.00332	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—GNG7—esophageal cancer	0.0028	0.00322	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—ADCYAP1—esophageal cancer	0.00276	0.00317	CbGpPWpGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.00269	0.00309	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—CXCL2—esophageal cancer	0.00266	0.00305	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—XIAP—esophageal cancer	0.00263	0.00302	CbGpPWpGaD
Tasosartan—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.00259	0.00298	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—GDI2—esophageal cancer	0.00253	0.00291	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CTNNA1—esophageal cancer	0.00248	0.00285	CbGpPWpGaD
Tasosartan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.00247	0.00284	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CXCL2—esophageal cancer	0.00247	0.00284	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—ANXA1—esophageal cancer	0.00247	0.00284	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—SST—esophageal cancer	0.0024	0.00276	CbGpPWpGaD
Tasosartan—CYP3A4—digestive system—esophageal cancer	0.00239	0.0328	CbGeAlD
Tasosartan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.00236	0.00272	CbGpPWpGaD
Tasosartan—CYP3A4—Tryptophan metabolism—CYP1B1—esophageal cancer	0.00236	0.00271	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—GHRL—esophageal cancer	0.00234	0.00269	CbGpPWpGaD
Tasosartan—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.00233	0.00268	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PSME1—esophageal cancer	0.00231	0.00265	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PSME2—esophageal cancer	0.00231	0.00265	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—ANXA1—esophageal cancer	0.0023	0.00264	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—SST—esophageal cancer	0.00223	0.00257	CbGpPWpGaD
Tasosartan—CYP3A4—Tryptophan metabolism—CYP19A1—esophageal cancer	0.00222	0.00255	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—GHRL—esophageal cancer	0.00218	0.0025	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—NOTCH3—esophageal cancer	0.00218	0.0025	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—FBXW7—esophageal cancer	0.00214	0.00246	CbGpPWpGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.00204	0.00234	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—AKAP13—esophageal cancer	0.00196	0.00225	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—NOTCH2—esophageal cancer	0.00195	0.00224	CbGpPWpGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.00192	0.0022	CbGpPWpGaD
Tasosartan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.00191	0.00219	CbGpPWpGaD
Tasosartan—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.00188	0.00216	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—KMT2D—esophageal cancer	0.00183	0.0021	CbGpPWpGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.00182	0.00209	CbGpPWpGaD
Tasosartan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.00179	0.00206	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—PDE4D—esophageal cancer	0.00179	0.00206	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—AKAP13—esophageal cancer	0.00178	0.00204	CbGpPWpGaD
Tasosartan—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.00177	0.00203	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.00175	0.00201	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—TGFBR2—esophageal cancer	0.00173	0.00199	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—GNG7—esophageal cancer	0.0017	0.00196	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—SMAD4—esophageal cancer	0.00164	0.00188	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—ADCYAP1—esophageal cancer	0.00163	0.00187	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—PDE4D—esophageal cancer	0.00163	0.00187	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—GNG7—esophageal cancer	0.00155	0.00178	CbGpPWpGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.00154	0.00177	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.00154	0.00177	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—CXCL2—esophageal cancer	0.0015	0.00172	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—WWOX—esophageal cancer	0.00149	0.00171	CbGpPWpGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.00145	0.00167	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.00143	0.00164	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—FKBP1A—esophageal cancer	0.00142	0.00163	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.00141	0.00162	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—ANXA1—esophageal cancer	0.0014	0.0016	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—WIF1—esophageal cancer	0.00139	0.00159	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CXCL2—esophageal cancer	0.00136	0.00157	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—SST—esophageal cancer	0.00136	0.00156	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—HIF1A—esophageal cancer	0.00134	0.00154	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.00133	0.00153	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—GHRL—esophageal cancer	0.00132	0.00152	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.00131	0.0015	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—KDR—esophageal cancer	0.00128	0.00147	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CSNK1A1—esophageal cancer	0.00128	0.00147	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—ANXA1—esophageal cancer	0.00127	0.00146	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—SST—esophageal cancer	0.00123	0.00142	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	0.00121	0.00139	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—NOTCH1—esophageal cancer	0.00121	0.00139	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—GHRL—esophageal cancer	0.0012	0.00138	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PFN1—esophageal cancer	0.0012	0.00137	CbGpPWpGaD
Tasosartan—AGTR1—G alpha (q) signalling events—PIK3CA—esophageal cancer	0.00118	0.00135	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CREBBP—esophageal cancer	0.0011	0.00126	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.00108	0.00124	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—EGFR—esophageal cancer	0.00108	0.00124	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—ELMO1—esophageal cancer	0.00107	0.00123	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.00105	0.00121	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—AKAP13—esophageal cancer	0.00105	0.00121	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.00103	0.00118	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—PIK3CA—esophageal cancer	0.00103	0.00118	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.00102	0.00117	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—NOS3—esophageal cancer	0.000981	0.00113	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000969	0.00111	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000965	0.00111	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PDE4D—esophageal cancer	0.000961	0.0011	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—PIK3CA—esophageal cancer	0.000935	0.00107	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—ERBB2—esophageal cancer	0.000918	0.00105	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—GNG7—esophageal cancer	0.000914	0.00105	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—XIAP—esophageal cancer	0.000856	0.000984	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.00082	0.000943	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CCND1—esophageal cancer	0.000811	0.000932	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CTNNA1—esophageal cancer	0.00081	0.00093	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000809	0.00093	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CXCL2—esophageal cancer	0.000805	0.000925	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CDKN1A—esophageal cancer	0.000784	0.000901	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000771	0.000886	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000761	0.000874	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PSME2—esophageal cancer	0.000752	0.000864	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PSME1—esophageal cancer	0.000752	0.000864	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—ANXA1—esophageal cancer	0.000748	0.00086	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—EP300—esophageal cancer	0.000746	0.000858	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—SST—esophageal cancer	0.000728	0.000836	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—NOTCH3—esophageal cancer	0.000709	0.000815	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—GHRL—esophageal cancer	0.000709	0.000815	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—FBXW7—esophageal cancer	0.000698	0.000802	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—MYC—esophageal cancer	0.00065	0.000747	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—NOTCH2—esophageal cancer	0.000636	0.000731	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—EGFR—esophageal cancer	0.000636	0.000731	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—TGFBR2—esophageal cancer	0.000564	0.000648	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PIK3CA—esophageal cancer	0.000552	0.000634	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—SMAD4—esophageal cancer	0.000534	0.000614	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—TP53—esophageal cancer	0.000534	0.000614	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—HIF1A—esophageal cancer	0.000437	0.000502	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—KDR—esophageal cancer	0.000418	0.00048	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—SLC52A3—esophageal cancer	0.000415	0.000476	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—BLVRB—esophageal cancer	0.000415	0.000476	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—NOTCH1—esophageal cancer	0.000394	0.000452	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CREBBP—esophageal cancer	0.000357	0.00041	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CA1—esophageal cancer	0.000352	0.000405	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—SLC10A2—esophageal cancer	0.000352	0.000405	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—EGFR—esophageal cancer	0.000351	0.000403	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000335	0.000385	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CA2—esophageal cancer	0.000322	0.00037	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—NOS3—esophageal cancer	0.00032	0.000367	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—PIK3CA—esophageal cancer	0.000305	0.00035	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PLCE1—esophageal cancer	0.0003	0.000344	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ADH7—esophageal cancer	0.0003	0.000344	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—ERBB2—esophageal cancer	0.000299	0.000344	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CCND1—esophageal cancer	0.000264	0.000304	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ADH1B—esophageal cancer	0.000263	0.000302	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CDKN1A—esophageal cancer	0.000256	0.000294	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—TYMP—esophageal cancer	0.000251	0.000289	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP26A1—esophageal cancer	0.000244	0.000281	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—EP300—esophageal cancer	0.000243	0.000279	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ALOX15—esophageal cancer	0.000238	0.000274	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—TPI1—esophageal cancer	0.000227	0.000261	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GSTO1—esophageal cancer	0.000227	0.000261	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ALDOB—esophageal cancer	0.000218	0.00025	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—MYC—esophageal cancer	0.000212	0.000243	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GAPDH—esophageal cancer	0.00021	0.000241	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CRABP1—esophageal cancer	0.000208	0.000239	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—EGFR—esophageal cancer	0.000207	0.000238	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GNG7—esophageal cancer	0.000198	0.000227	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ALDH2—esophageal cancer	0.000185	0.000213	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PIK3CA—esophageal cancer	0.00018	0.000207	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GSTT1—esophageal cancer	0.000176	0.000202	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP2A6—esophageal cancer	0.000174	0.0002	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—TP53—esophageal cancer	0.000174	0.0002	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ENO1—esophageal cancer	0.000165	0.00019	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PTGS1—esophageal cancer	0.000165	0.00019	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PSME1—esophageal cancer	0.000163	0.000187	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PSME2—esophageal cancer	0.000163	0.000187	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP1B1—esophageal cancer	0.00014	0.000161	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP19A1—esophageal cancer	0.000132	0.000152	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—HMOX1—esophageal cancer	0.00012	0.000138	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ABCB1—esophageal cancer	0.000116	0.000133	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CREBBP—esophageal cancer	7.72e-05	8.87e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—NOS3—esophageal cancer	6.91e-05	7.94e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PTGS2—esophageal cancer	6.32e-05	7.26e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—EP300—esophageal cancer	5.26e-05	6.04e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PIK3CA—esophageal cancer	3.89e-05	4.47e-05	CbGpPWpGaD
